Literature DB >> 12692203

Colorectal carcinoma: diagnostic, prognostic, and molecular features.

Carolyn C Compton1.   

Abstract

Surgical resection is the primary treatment modality for colorectal cancer, and the pathologic assessment of the resection specimen provides data that is essential for patient management, including the estimation of postoperative outcome and the rationale for adjuvant therapy. The essential elements of the pathological assessment of colorectal cancer resection specimens include the pathologic determination of TNM stage, tumor type, histologic grade, status of resection margins, and vascular invasion. The prognostic and/or predictive value of these elements, as well as guidelines for their derivation and interpretation, are reviewed in detail. Other tissue-based prognostic factors that are strongly suggested by existing data to have stage-independent prognostic value or to predict response to adjuvant therapy but that have not yet been validated for routine patient care are also reviewed. These include perineural invasion, tumor border configuration, host immune response to tumor, and molecular features such as microsatellite instability or loss of heterozygosity of chromosome 18. The need for high-quality, reproducible pathologic data in the care of the colorectal cancer patient, and the dependence of that data on standardization of all aspects of pathological assessment, is emphasized.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12692203     DOI: 10.1097/01.MP.0000062859.46942.93

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  111 in total

1.  Association of APC I1307K and E1317Q polymorphisms with colorectal cancer among Egyptian subjects.

Authors:  Camelia Abdel-Malak; Hossam Darwish; Afaf Elsaid; Fatma El-Tarapely; Rami Elshazli
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

2.  Metastatic recurrence of early-stage colorectal cancer is linked to loss of heterozygosity on chromosomes 4 and 14q.

Authors:  F Al-Mulla; S AlFadhli; A H Al-Hakim; J J Going; M S Bitar
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

Review 3.  Molecular classification and correlates in colorectal cancer.

Authors:  Shuji Ogino; Ajay Goel
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

4.  Association of monoallelic MUTYH mutation among Egyptian patients with colorectal cancer.

Authors:  Afaf Elsaid; Rami Elshazli; Fatma El-Tarapely; Hossam Darwish; Camelia Abdel-Malak
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

5.  Clinicopathological significance and prognostic value of LRP16 expression in colorectal carcinoma.

Authors:  Hong Qing Xi; Po Zhao; Wei Dong Han
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

6.  Pathological reporting of colorectal cancer specimens: a retrospective survey in an academic Canadian pathology department.

Authors:  Nancy G Chan; Anil Duggal; Michele M Weir; David K Driman
Journal:  Can J Surg       Date:  2008-08       Impact factor: 2.089

7.  Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers.

Authors:  Frank A Sinicrope; Rafaela L Rego; Nathan R Foster; Stephen N Thibodeau; Steven R Alberts; Harold E Windschitl; Daniel J Sargent
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

8.  The pathologist's role in rectal cancer patient assessments.

Authors:  Joseph E Willis
Journal:  Clin Colon Rectal Surg       Date:  2007-08

9.  Ki-ras gene mutations, LOH of the APC and DCC genes, and microsatellite instability in primary colorectal carcinoma are not associated with micrometastases in pericolonic lymph nodes or with patients' survival.

Authors:  N P Zauber; C Wang; P S Lee; T C Redondo; D T Bishop; A Goel
Journal:  J Clin Pathol       Date:  2004-09       Impact factor: 3.411

10.  CD169 identifies an activated CD8(+) T cell subset in regional lymph nodes that predicts favorable prognosis in colorectal cancer patients.

Authors:  Jiali Zhang; Jing Xu; Rong-Xin Zhang; Yi Zhang; Qing-Jian Ou; Jin-Qing Li; Ze-Zhou Jiang; Xiao-Jun Wu; Yu-Jing Fang; Limin Zheng
Journal:  Oncoimmunology       Date:  2016-04-29       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.